Rectal advancement flap plus adipose lipofilling (RAFAL) for the treatment of rectourethral fistulas after radical prostatectomy.
Aged
Humans
Male
Mesenchymal Stem Cell Transplantation
/ methods
Mesenchymal Stem Cells
Middle Aged
Postoperative Complications
/ etiology
Prostatectomy
/ adverse effects
Prostatic Neoplasms
/ surgery
Rectal Fistula
/ etiology
Rectum
/ surgery
Surgical Flaps
Treatment Outcome
Urethral Diseases
/ etiology
Urinary Fistula
/ etiology
LIPOGEMS®
Mesenchymal stem cells (MSCs)
Rectourethral fistula
Transanal advancement flap
Journal
Techniques in coloproctology
ISSN: 1128-045X
Titre abrégé: Tech Coloproctol
Pays: Italy
ID NLM: 9613614
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
12
03
2019
accepted:
05
09
2019
pubmed:
20
9
2019
medline:
31
7
2020
entrez:
20
9
2019
Statut:
ppublish
Résumé
Rectourethral fistula (RUF) is a rare but significant complication after radical prostatectomy. Many different approaches have been used, but none of them has become the standard of care. We present our series of seven patients treated with a transanal rectal advancement flap plus the injection of mesenchymal stem cells, to facilitate the healing of the fistula. Mesenchymal cells were obtained by a new mechanical device known as LIPOGEMS After a median follow-up of 53 months (range 6-163 months), 2 out of 7 patients experienced RUF recurrence. In both cases recurrence was successfully treated by the York-Mason technique in one case and by redo RAFAL in the other. Success rate of RAFAL was 71% (5 of 7). The total success rate of primary RAFAL and redo- RAFAL was 85.7% (6 of 7). No short- or long-term complications were seen. In our patient population this new procedure was safe and effective.
Sections du résumé
BACKGROUND
BACKGROUND
Rectourethral fistula (RUF) is a rare but significant complication after radical prostatectomy. Many different approaches have been used, but none of them has become the standard of care.
METHODS
METHODS
We present our series of seven patients treated with a transanal rectal advancement flap plus the injection of mesenchymal stem cells, to facilitate the healing of the fistula. Mesenchymal cells were obtained by a new mechanical device known as LIPOGEMS
RESULTS
RESULTS
After a median follow-up of 53 months (range 6-163 months), 2 out of 7 patients experienced RUF recurrence. In both cases recurrence was successfully treated by the York-Mason technique in one case and by redo RAFAL in the other. Success rate of RAFAL was 71% (5 of 7). The total success rate of primary RAFAL and redo- RAFAL was 85.7% (6 of 7). No short- or long-term complications were seen.
CONCLUSIONS
CONCLUSIONS
In our patient population this new procedure was safe and effective.
Identifiants
pubmed: 31535239
doi: 10.1007/s10151-019-02078-8
pii: 10.1007/s10151-019-02078-8
doi:
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003-1007Références
Colorectal Dis. 2011 Aug;13(8):918-20
pubmed: 20402736
Neurourol Urodyn. 2018 Sep;37(7):2286-2287
pubmed: 30152530
Prostate Cancer. 2011;2011:629105
pubmed: 22110993
J Urol. 2010 Feb;183(2):608-12
pubmed: 20018317
Int J Artif Organs. 2008 Jun;31(6):467-79
pubmed: 18609499
Asian J Urol. 2018 Jul;5(3):149-154
pubmed: 29988864